|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.4 GBX | -5.41% |
|
-9.68% | -70.21% |
| May. 20 | IQ-AI subsidiary gets second FDA rare paediatric disease designation | AN |
| May. 20 | IQ-AI's Imaging Biometrics Gets Second Rare Disease Designation for Drug Candidate | MT |
IQ-AI Limited reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was GBP 0.282652 million compared to GBP 0.255609 million a year ago. Net loss was GBP 0.300473 million compared to GBP 0.330584 million a year ago.
Basic loss per share from continuing operations was GBP 0.0016 compared to GBP 0.0018 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -70.21% | 3.94M | |
| -21.57% | 8.54B | |
| +68.22% | 4.32B | |
| -1.18% | 2.53B | |
| -9.63% | 2.46B | |
| -38.23% | 2.48B | |
| -7.85% | 1.9B | |
| -17.74% | 1.59B | |
| -39.48% | 1.23B | |
| +9.68% | 1.13B |
IQ-AI LIMITED 